title: NF-κB activation is required for the transition of pulmonary inflammation to muscle atrophy.
abstract: Disease exacerbations and muscle wasting comprise negative prognostic factors of chronic obstructive pulmonary disease (COPD). Transient systemic inflammation and malnutrition have been implicated in skeletal muscle wasting after acute exacerbations of COPD. However, the interactions between systemic inflammation and malnutrition in their contributions to muscle atrophy, as well as the molecular basis underlying the transition of systemic inflammation to muscle atrophy, remain unresolved. Pulmonary inflammation was induced in mice by an intratracheal instillation of LPS to model acute disease exacerbation. Systemic inflammation, nutritional intake, and body and muscle weights were determined. Muscle inflammatory signaling and atrophy signaling were examined, and the effect of the muscle-specific inactivation of NF-κB on muscle atrophy was assessed in genetically modified mice. The intratracheal LPS instillation was followed by markedly elevated circulating cytokine concentrations and NF-κB activation in extrapulmonary tissues, including skeletal muscle. The administration of intratracheal LPS increased the expression of muscle E3 ubiquitin ligases, which govern muscle proteolysis, in particular MuRF1, and caused a rapid loss of muscle mass. Reduced food intake only partly accounted for the observed muscle atrophy, and did not activate NF-κB in muscle. Rather, plasma transfer experiments revealed the presence of NF-κB-signaling and atrophy-signaling properties in the circulation of intratracheal LPS-treated mice. The genetic inhibition of muscle NF-κB activity suppressed intratracheal LPS-induced MuRF1 expression and resulted in a significant sparing of muscle tissue. Systemic inflammation and malnutrition contribute to the muscle wasting induced by acute pulmonary inflammation via distinct mechanisms, and muscle NF-κB activation is required for the transition from inflammatory to muscle atrophy signaling.
authors.affiliation: Department of Respiratory Medicine, NUTRIM School of Nutrition, Toxicology, and Metabolism, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands. r.langen@maastrichtuniversity.nl
authors.forename: Ramon C J
authors.initials: RC
authors.lastname: Langen
authors.forename: Astrid
authors.initials: A
authors.lastname: Haegens
authors.forename: Juanita H J
authors.initials: JH
authors.lastname: Vernooy
authors.forename: Emiel F M
authors.initials: EF
authors.lastname: Wouters
authors.forename: Menno P J
authors.initials: MP
authors.lastname: de Winther
authors.forename: Harald
authors.initials: H
authors.lastname: Carlsen
authors.forename: Chad
authors.initials: C
authors.lastname: Steele
authors.forename: Steven E
authors.initials: SE
authors.lastname: Shoelson
authors.forename: Annemie M W J
authors.initials: AM
authors.lastname: Schols
mesh_terms: D000818:Animals; D015870:Gene Expression; D008070:Lipopolysaccharides / Q000008:administration & dosage; D051379:Mice; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal / Q000378:metabolism / Q000473:pathology*; D009133:Muscular Atrophy; D016328:NF-kappa B / Q000378:metabolism*; D011014:Pneumonia / Q000378:metabolism / Q000473:pathology*; D015398:Signal Transduction
chemical_list: D008070:Lipopolysaccharides; D016328:NF-kappa B